BrainStorm Cell Therapeutics

Historical price data

BrainStorm Cell Therapeutics is a clinical-stage biotechnology company singularly focused on defeating neurodegenerative diseases through its innovative NurOwn® autologous cellular therapy platform. Its most advanced program targets Amyotrophic Lateral Sclerosis (ALS), where it has secured a Special Protocol Assessment (SPA) with the FDA for a confirmatory Phase 3b trial following mixed but promising biomarker data from its prior Phase 3 study. The company's strategy hinges on validating NurOwn's multimodal mechanism of action in ALS to secure regulatory approval, while leveraging the platform's potential for expansion into other neurodegenerative indications with high unmet need.

The NurOwn® platform is a proprietary, autologous cellular technology that differentiates a patient's own bone marrow-derived mesenchymal stem cells (MSCs) to secrete high levels of neurotrophic factors (NTFs) and immunomodulatory cytokines, which are then delivered via intrathecal injection to target neurodegenerative disease pathways.

BrainStorm competes in ALS with approved small molecules (Relyvrio, Radicava) and targeted gene therapy (Qalsody). Its key differentiator is its autologous, multimodal cell-based approach designed for sporadic ALS. Primary competition comes from other late-stage neuroprotective agents and the high bar for demonstrating efficacy in this difficult disease.